Design of pyrazolo-pyrimidines as 11β-HSD1 inhibitors through optimisation of molecular electrostatic potential

MedChemComm

Volumn 6, Issue 5, 2015, Pages 926-934

  Robb, Graeme R ^a   Boyd, Scott ^a   Davies, Christopher D ^a   Dossetter, Alexander G ^a   Goldberg, Frederick W ^a   Kemmitt, Paul D ^a   Scott, James S ^a   Swales, John G ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; OXIDOREDUCTASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING KINETICS; BLOOD BRAIN BARRIER; DRUG CONFORMATION; DRUG DESIGN; DRUG PENETRATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; HYDROGEN BOND; MOLECULAR ELECTROSTATIC POTENTIAL; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTUM MECHANICS; STATIC ELECTRICITY;

EID: 84929322078     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c5md00043b     Document Type: Article

References (35)

1. S. C. Walpole D. Prieto-Merino P. Edwards J. Cleland G. Stevens I. Roberts The weight of nations: an estimation of adult human biomass BMC Public Health 2012 12 439
2. R. Thieringer A. Hermanowski-Vosatka Inhibition of 11β-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role? Expert Rev. Cardiovasc. Ther. 2005 3 911 924
3. P. Bjorntorp G. Holm R. Rosmond Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus Diabetic Med. 1999 16 373 383
4. B. R. Walker Glucocorticoids and cardiovascular disease Eur. J. Endocrinol. 2007 157 545 559
5. J. W. Tomlinson E. A. Walker I. J. Bujalska N. Draper G. G. Lavery M. S. Cooper M. Hewison P. M. Stewart 11β-hydroxysteroid dehydrogenase type 1: A tissue-specific regulator of glucocorticoid response Endocr. Rev. 2004 25 831 866
6. C. R. W. Edwards R. Benediktsson R. S. Lindsay J. R. Seckl 11β-Hydroxysteroid dehydrogenases: key enzymes in determining tissue-specific glucocorticoid effects Steroids 1996 61 263 269
7. E. A. Walker P. M. Stewart 11beta-Hydroxysteroid dehydrogenase: unexpected connections Trends Endocrinol. Metab. 2003 14 334 339
8. J. L. W. Yau J. Noble C. J. Kenyon C. Hibberd Y. Kotelevtsev J. J. Mullins J. R. Seckl Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments Proc. Natl. Acad. Sci. U. S. A. 2001 98 4716 4721
9. M. C. Holmes R. N. Carter J. Noble S. Chitnis A. Dutia J. M. Paterson J. J. Mullins J. R. Seckl J. L. W. Yau 11β-Hydroxysteroid Dehydrogenase Type 1 Expression Is Increased in the Aged Mouse Hippocampus and Parietal Cortex and Causes Memory Impairments J. Neurosci. 2010 30 6916 6920
10. T. C. Sandeep J. L. W. Yau A. M. J. MacLullich J. Noble I. J. Deary B. R. Walker J. R. Seckl 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics Proc. Natl. Acad. Sci. U. S. A. 2004 101 6734 6739
11. J. S. Scott F. W. Goldberg A. V. Turnbull Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) J. Med. Chem. 2014 57 4466 4486
12. S. P. Webster T. D. Pallin 11β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents Expert Opin. Ther. Pat. 2007 17 1407 1422
13. C. D. Boyle T. J. Kowalski 11β-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents Expert Opin. Ther. Pat. 2009 19 801 825
14. S. A. Morgan J. W. Tomlinson 11β-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes Expert Opin. Invest. Drugs 2010 19 1067 1076
15. J. Rosenstock S. Banarer V. A. Fonseca S. E. Inzucchi W. Sun W. Yao G. Hollis R. Flores R. Levy W. V. Williams J. R. Seckl R Huber for the INCB13739-202 Principal Investigators The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy Diabetes Care 2010 33 1516 1522
16. D. R. Bauman A. Whitehead L. C. Contino J. Cui M. Garcia-Calvo X. Gu N. Kevin X. Ma L. Pai K. Shah X. Shen S. Stribling H. J. Zokian J. Metzger D. E. Shevell S. T. Waddell Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension Bioorg. Med. Chem. Lett. 2013 23 3650 3653
17. S. Shah A. Hermanowski-Vosatka K. Gibson R. A. Ruck G. Jia J. Zhang P. M. T. Hwang N. W. Ryan R. B. Langdon P. U. Feig Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension J. Am. Soc. Hypertens. 2011 5 166 176
18. J. S. Scott S. S. Bowker J. deSchoolmeester S. Gerhardt D. Hargreaves E. Kilgour A. Lloyd R. M. Mayers W. McCoull N. J. Newcombe D. Ogg M. J. Packer A. Rees J. Revill P. Schofield N. Selmi J. Swales G. Whittamore P. R. O. Discovery of a Potent, Selective, and Orally Bioavailable Acidic 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitor: Discovery of 2-[(3S)-1-[5-(Cyclohexylcarbamoyl)-6-propylsulfanyl pyridin-2-yl]-3-piperidyl]acetic Acid (AZD4017) J. Med. Chem. 2012 55 5951 5964
19. F. W. Goldberg A. G. Leach J. S. Scott W. L. Snelson S. D. Groombridge C. S. Donald S. N. L. Bennett C. Bodin P. M. Gutierrez A. C. Gyte Free-Wilson and Structural Approaches to Co-optimizing Human and Rodent Isoform Potency for 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors J. Med. Chem. 2012 55 10652 10661
20. P. H. Bisschop M. J. H. J. Dekker W. Osterthun J. Kwakkel J. J. Anink A. Boelen U. A. Unmehopa J. W. Koper S. W. J. Lamberts P. M. Stewart D. F. Swaab E. Fliers Expression of 11β-Hydroxysteroid Dehydrogenase Type 1 in the Human Hypothalamus J. Neuroendocrinol. 2013 25 425 432
21. E. Savontaus I. M. Conwell S. L. Wardlaw Effects of adrenalectomy on AGRP, POMC, NPY and CART gene expression in the basal hypothalamus of fed and fasted rats Brain Res. 2002 958 130 138
22. S. Beaulieu B. Gagné N. Barden Glucocorticoid Regulation of Proopiomelanocortin Messenger Ribonucleic Acid Content of Rat Hypothalamus Mol. Endocrinol. 1988 2 727 731
23. P. U. Feig S. Shah A. Hermanowski-Vosatka D. Plotkin M. S. Springer S. Donahue C. Thach E. J. Klein E. Lai K. D. Kaufman Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome Diabetes, Obes. Metab. 2011 13 498 504
24. F. W. Goldberg A. G. Dossetter J. S. Scott G. R. Robb S. Boyd S. D. Groombridge P. D. Kemmitt T. Sjogren P. M. Gutierrez J. deSchoolmeester J. G. Swales A. V. Turnbull M. J. Wild Optimization of Brain Penetrant 11β-Hydroxysteroid Dehydrogenase Type I Inhibitors and in vivo Testing in Diet-Induced Obese Mice J. Med. Chem. 2014 57 970 986
25. H. Van d. W. G. Camenisch G. Folkers J. R. Chretien O. A. Raevsky Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors J. Drug Targeting 1998 6 151 165
26. A. K. Ghose T. Herbertz R. L. Hudkins B. D. Dorsey J. P. Mallamo Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery ACS Chem. Neurosci. 2012 3 50 68
27. H. Pajouhesh G. R. Lenz Medicinal chemical properties of successful central nervous system drugs NeuroRx 2005 2 541 553
28. P. D. Leeson B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discovery 2007 6 881 890
29. A. L. Hopkins C. R. Groom A. Alex Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004 9 430 431
30. P. Ertl B. Rohde P. Selzer Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties J. Med. Chem. 2000 43 3714 3717
31. P. W. Kenny Prediction of hydrogen bond basicity from computed molecular electrostatic properties: implications for comparative molecular field analysis J. Chem. Soc., Perkin Trans. 2 1994 199 202
32. P. W. Kenny Hydrogen Bonding, Electrostatic Potential, and Molecular Design J. Chem. Inf. Model. 2009 49 1234 1244
33. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, D. J. Fox, Gaussian 09, Revision B.01. Gaussian, Inc., Wallingford CT, 2010
34. S. H. Yalkowsky S. C. Valvani Solubility and partitioning I: Solubility of nonelectrolytes in water J. Pharm. Sci. 1980 69 912 922
35. E. Griffen A. G. Leach G. R. Robb D. J. Warner Matched Molecular Pairs as a Medicinal Chemistry Tool J. Med. Chem. 2011 54 7739 7750